[1] |
Palanivel JA, Macbeth AE, Chetty NC, et al. An insight into JAK-STAT signalling in dermatology[J]. Clin Exp Dermatol, 2014, 39(4): 513⁃518. DOI: 10.1111/ced.12273.
|
[2] |
Ghoreschi K, Laurence A, O′Shea JJ. Janus kinases in immune cell signaling[J]. Immunol Rev, 2009, 228(1): 273⁃287. DOI: 10.1111/j.1600⁃065X.2008.00754.x.
|
[3] |
Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP⁃690,550)[J]. J Immunol, 2011, 186(7): 4234⁃4243. DOI: 10.4049/jimmunol.1003668.
|
[4] |
Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate⁃to⁃severe chronic plaque psoriasis: a phase 3 randomised non⁃inferiority trial[J]. Lancet, 2015, 386(9993): 552⁃561. DOI: 10.1016/S0140⁃6736(14)62113⁃9.
|
[5] |
Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis[J]. Br J Dermatol, 2013, 169(1): 137⁃145. DOI: 10.1111/bjd.12266.
|
[6] |
Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis[J]. IDrugs, 2010, 13(6): 394⁃403.
|
[7] |
Punwani N, Burn T, Scherle P, et al. Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor[J]. Br J Dermatol, 2015, 173(4): 989⁃997. DOI: 10.1111/bjd.13994.
|
[8] |
Abroun S, Saki N, Ahmadvand M, et al. STATs: An old story, yet mesmerizing[J]. Cell J, 2015, 17(3): 395⁃411.
|
[9] |
Shi X, Jin L, Dang E, et al. IL⁃17A upregulates keratin 17 in keratinocytes through STAT1⁃ and STAT3⁃dependent mechanisms[J]. J Invest Dermatol, 2011, 131(12): 2401⁃2408. DOI: 10.1038/jid.2011.222.
|
[10] |
Andrés RM, Montesinos MC, Navalón P, et al. NF⁃κB and STAT3 inhibition as a therapeutic strategy in psoriasis: in vitro and in vivo effects of BTH[J]. J Invest Dermatol, 2013, 133(10): 2362⁃2371. DOI: 10.1038/jid.2013.182.
|
[11] |
Kim BH, Lee JM, Jung YG, et al. Phytosphingosine derivatives ameliorate skin inflammation by inhibiting NF⁃κB and JAK/STAT signaling in keratinocytes and mice[J]. J Invest Dermatol, 2014, 134(4): 1023⁃1032. DOI: 10.1038/jid.2013.453.
|
[12] |
Miyoshi K, Takaishi M, Nakajima K, et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA⁃21, a Stat3 inhibitor[J]. J Invest Dermatol, 2011, 131(1): 108⁃117. DOI: 10.1038/jid.2010.255.
|
[13] |
Moustafa F, Feldman SR. A review of phosphodiesterase⁃inhibition and the potential role for phosphodiesterase 4⁃inhibitors in clinical dermatology[J]. Dermatol Online J, 2014, 20(5): 22608.
|
[14] |
Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phaseⅢ, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1)[J]. J Am Acad Dermatol, 2015, 73(1): 37⁃49. DOI: 10.1016/j.jaad.2015.03.049.
|
[15] |
Akama T, Baker SJ, Zhang YK, et al. Discovery and structure⁃activity study of a novel benzoxaborole anti⁃inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis[J]. Bioorg Med Chem Lett, 2009, 19(8): 2129⁃2132. DOI: 10.1016/j.bmcl.2009.03.007.
|
[16] |
Muramoto K, Goto M, Inoue Y, et al. E6201, a novel kinase inhibitor of mitogen⁃activated protein kinase/extracellular signal⁃regulated kinase kinase⁃1 and mitogen⁃activated protein kinase/extracellular signal⁃regulated kinase kinase kinase⁃1: in vivo effects on cutaneous inflammatory responses by topical administration[J]. J Pharmacol Exp Ther, 2010, 335(1): 23⁃31. DOI: 10.1124/jpet.110.168583.
|
[17] |
Crawshaw AA, Griffiths CE, Young HS. Investigational VEGF antagonists for psoriasis[J]. Expert Opin Investig Drugs, 2012, 21(1): 33⁃43. DOI: 10.1517/13543784.2012.636351.
|
[18] |
Halin C, Fahrngruber H, Meingassner JG, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor [J]. Am J Pathol, 2008, 173(1): 265⁃277. DOI: 10.2353/ajpath.2008.071074.
|
[19] |
Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: Results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis[J]. Acta Derm Venereol, 2015, 95(5): 542⁃548. DOI: 10.2340/00015555⁃2047.
|
[20] |
Xiao S, Yosef N, Yang J, et al. Small⁃molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms[J]. Immunity, 2014, 40(4): 477⁃489. DOI: 10.1016/j.immuni.2014.04.004.
|